StockData
Atrium Therapeutics, Inc. logo

Atrium Therapeutics, Inc. (RNA) stock

RNANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$6.98+0.34 (+5.12%)

Close on Nov 19, 2026Market cap $119.40MP/E –Yield –

Atrium Therapeutics net income

Net income is the profit left for shareholders after every expense, interest and tax.

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$4.27M–
Q2 FY2026Jun 30, 2026-$20.19M–
Q1 FY2026Mar 31, 2026-$16.63M–
Q3 FY2025Sep 30, 2025-$37.00K–
Q2 FY2025Jun 30, 2025-$12.88M–
Q1 FY2025Mar 31, 2025-$7.45M–

More Atrium Therapeutics figures

See a number that looks wrong?